Shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) have been given an average rating of “Hold” by the ten research firms that are currently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and four have given a buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $5.55.

Several equities analysts recently issued reports on the stock. Zacks Investment Research raised shares of Achillion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.25 price objective on the stock in a report on Monday, November 13th. Robert W. Baird lowered shares of Achillion Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $5.00 price objective on the stock. in a report on Thursday, August 10th. Maxim Group set a $7.00 price objective on shares of Achillion Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 9th. BidaskClub raised shares of Achillion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, August 16th. Finally, Chardan Capital cut their price objective on shares of Achillion Pharmaceuticals from $5.00 to $4.00 and set a “neutral” rating on the stock in a report on Wednesday, August 9th.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Cambridge Investment Research Advisors Inc. grew its holdings in Achillion Pharmaceuticals by 3.6% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 23,130 shares of the biopharmaceutical company’s stock worth $106,000 after purchasing an additional 800 shares during the last quarter. Schwab Charles Investment Management Inc. grew its holdings in Achillion Pharmaceuticals by 0.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 457,341 shares of the biopharmaceutical company’s stock worth $2,100,000 after purchasing an additional 2,850 shares during the last quarter. Bank of Montreal Can grew its holdings in Achillion Pharmaceuticals by 6.4% in the second quarter. Bank of Montreal Can now owns 56,715 shares of the biopharmaceutical company’s stock worth $260,000 after purchasing an additional 3,410 shares during the last quarter. Wells Fargo & Company MN grew its holdings in Achillion Pharmaceuticals by 1.8% in the second quarter. Wells Fargo & Company MN now owns 219,647 shares of the biopharmaceutical company’s stock worth $1,009,000 after purchasing an additional 3,827 shares during the last quarter. Finally, SG Americas Securities LLC grew its holdings in Achillion Pharmaceuticals by 18.6% in the second quarter. SG Americas Securities LLC now owns 26,429 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 4,144 shares during the last quarter. 74.81% of the stock is currently owned by institutional investors and hedge funds.

Achillion Pharmaceuticals (NASDAQ ACHN) opened at $3.43 on Friday. Achillion Pharmaceuticals has a 1 year low of $2.95 and a 1 year high of $5.66.

Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.04. During the same quarter in the previous year, the business earned ($0.15) EPS. research analysts predict that Achillion Pharmaceuticals will post -0.63 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Achillion Pharmaceuticals, Inc. (ACHN) Given Average Recommendation of “Hold” by Brokerages” was posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.watchlistnews.com/achillion-pharmaceuticals-inc-achn-given-average-recommendation-of-hold-by-brokerages/1713616.html.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Analyst Recommendations for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.